Denmark GDP Jumps 5.4%, but Novo Nordisk Boom Barely Lifts Real Income

Nationalbanken's 4% growth forecast rests on drug production abroad that uses few Danish workers. The krone has needed support instead of strengthening, and Novo's guidance suggests the pharmaceutical boost is already fading.

Statistics Denmark's quarterly accounts put a number on the gap Danmarks Nationalbank described on September 23. In the first half of 2026, Danish real GDP, measured in chained volumes, was 5.4% higher than a year earlier. Nominal GDP was up only 2.6%. Gross national income, which adjusts output for income flowing to and from the rest of the world, rose 1.9% in current prices. Statistics Denmark's measure of real GNI, which also allows for the prices Denmark pays and receives, rose 0.1%.

That is the arithmetic behind the central bank's new forecast. Nationalbanken now expects GDP growth of 4.0% in 2026, up from 1.8% in March, followed by 2.3% in 2027 and 2.0% in 2028. It says growth "has been driven primarily by an extraordinary increase in the pharmaceutical industry's output abroad in the first half of the year." That increase came mainly from Novo Nordisk's US business, after its pricing agreement with the US administration and the approval of an oral version of Wegovy. The bank adds: "The high growth does not result in a corresponding increase in Danish prosperity measured by gross national income."

Volume up, value down

National-accounts rules explain how output can rise so fast in a country whose factories did not. A Danish-owned company that manufactures abroad while keeping economic ownership of the goods books the value added in Danish GDP. The plants, most of the workers and much of the capital sit outside Denmark.

The gap between real and nominal growth has a second cause. Novo agreed to cut US prices on selected weight-loss and diabetes drugs by up to 30% under the administration's most-favoured-nation arrangement. Volumes rose while prices fell, so real output jumped while the value of that output, and the income it generates, grew far less. The first half therefore shows Denmark producing a lot more medicine and earning only a little more from it.

The timing matters too. Statistics Denmark's first-quarter release showed GDP up 1.5% from the previous quarter; gross value added rose 1.7%, but only 0.5% excluding pharmaceuticals. In the second quarter GDP rose just 0.3%, and the agency said the pharmaceutical industry "did not contribute much" after its large first-quarter contribution. Gross value added excluding pharma grew 0.3%, against 0.4% overall. Most of the surge behind the 2026 forecast happened in a single quarter.

Three channels that matter more than interest rates

The composition of GDP does little to Danish interest rates. Nationalbanken's job is to hold the krone near its central rate of 7.46038 per euro. Its policy rate, 1.85% and 40 basis points below the ECB's, follows Frankfurt and moves independently only to defend the peg. The pharmaceutical surge reaches the domestic economy through three other routes.

Fiscal policy. Denmark's budget rules and the EU's deficit and debt limits are all measured against GDP. A GDP figure inflated by production abroad flatters those ratios and makes fiscal room look larger than the domestic economy can safely absorb. Governor Christian Kettel Thomsen said the government "should not boost demand any further than already set out in August" and should "exercise caution in using the full fiscal scope in the coming years." Part of that measured scope sits in Novo's foreign plants.

The krone. Pharmaceutical earnings converted into kroner should push the currency up. In 2026 the opposite happened. On August 7 the krone touched 7.4761 per euro, its weakest since the euro's launch in 1999. Nationalbanken intervened, with DKK 0.7 billion in June and net krone purchases of DKK 5.6 billion in August. Coverage of the interventions cited large public investment plans and record overseas spending by Danish companies. Income earned by plants abroad does not have to come home. Denmark's GDP boom has arrived without the currency inflow that would normally come with it. Danske Bank's chief economist has said a 0.1-point independent rate rise "can't be ruled out"; that would be a currency decision, not a response to growth.

Wages. Foreign plants do not hire Danish workers. That is why the central bank can forecast 4% growth, "with no signs of increased wage or price pressure," and inflation of 1.7% this year.

Novo's guidance points down

Novo's own numbers suggest the first-half surge will not repeat. Adjusted sales rose 2% at constant exchange rates in the first half, with the second quarter up 7%. Yet August's raised guidance still calls for full-year adjusted sales growth of minus 6% to 0%. If the two halves of 2025 were roughly equal, second-half sales must fall roughly 2% to 14% year on year to land in that range. That is a CTOL calculation, not company guidance.

Sales value and GDP volumes can diverge, as the first half showed. But a company guiding to shrinking sales, after cutting prices, is unlikely to keep adding volume at a pace that lifts national output. At its capital markets day on September 21, Novo set a 2030 ambition of revenue growth "in line with that of its industry peers," and its shares fell about 6% during the session. They closed 2.5% lower at DKK 252.25 on September 23.

CTOL view: The pharmaceutical boost to Danish GDP has already peaked. Our call: in at least one of Statistics Denmark's next two quarterly GDP releases, covering the third quarter (due in November) and the fourth quarter of 2026 (due in February 2027), gross value added excluding pharmaceuticals will grow faster than total gross value added, meaning pharma subtracts from growth. We are wrong if, in both releases, total gross value added grows as fast as or faster than gross value added excluding pharmaceuticals.

What the headline hides

None of this makes the domestic economy weak. Statistics Denmark's second-quarter data show growth spread across several industries, with exports and investment rising and employment up 0.2% on the quarter, though private and public consumption fell. Nationalbanken expects labour-market gains and rising incomes to support consumption.

The measurement problem remains. Denmark's reported growth rate increasingly tracks one company's global supply chain. The 2026 figure overstates domestic strength, and a 2027 slowdown driven by pharma will likely overstate domestic weakness. For fiscal planners and anyone pricing Danish demand, real GNI, employment and wages are more reliable guides than headline GDP. On the first half's evidence, real GNI is flat.

Denmark GDP Jumps 5.4%, but Novo Nordisk Boom Barely Lifts Real Income

Volume up, value down

Three channels that matter more than interest rates

Novo's guidance points down

What the headline hides

Sources

You May Also Like

Subscribe to our Newsletter